June 8-12, 2012, in Philadelphia | |||||
Company (Location) |
Product |
Description |
Indication |
Status |
Date |
Amylin Pharmaceuticals Inc. (San Diego) |
Bydureon |
Exenatide extended-release for injectable suspension |
Type II diabetes |
Results from seven trials demonstrated improvements in A1C, fasting glucose, weight and pulse pressure, regardless of their baseline body weight; another trial showed it was associated with clinically significant and sustained improvements in glycemic control over four years; further data showed patients experienced improvements with A1C fasting glucose, weight and pulse pressure, regardless of baseline body weight |
6/11/12 |
Amylin Pharmaceuticals Inc. (San Diego) |
Byetta |
Exenatide |
Type II diabetes |
A European trial showed patients had greater glycemic durability and overall glycemic control when using Byetta than when using Amaryl |
6/11/12 |
Amylin Pharmaceuticals Inc. (San Diego) |
Symlin |
Pramlintide acetate |
Type I or Type II diabetes |
Data showed patients had more normal blood glucose measurements when Symlin was used with insulin |
6/11/12 |
Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (Indianapolis) |
Tradjenta |
Linagliptin; DPP-4 inhibitor |
Type II diabetes |
Results from a post-hoc analysis showed a 29% reduction in a urinary albumin-to-creatinine ratio with linagliptin plus angiotensin-converting enzyme inhibitors and angiotensin receptor blockers vs. ACEs/ARBs alone at 24 weeks |
6/12/12 |
Bristol-Myers Squibb Co. (New York) |
Dapagliflozin |
SGLT2 inhibitor |
Type II diabetes |
Phase III data showed 10 mg demonstrated reductions in blood sugar levels compared to placebo at 24 weeks when either agent was added to existing Januvia therapy |
6/12/12 |
Cebix Inc. (La Jolla, Calif.) |
Ersatta |
Long-acting form of C-peptide |
Type I diabetes |
Phase I data demonstrated it was well tolerated with no adverse events |
6/12/12 |
Diartis Pharmaceuticals Inc. (Mountain View, Calif.) |
VRS-859 |
Exenatide-XTEN; a long-acting GLP-1 analogue |
Type II diabetes |
Phase I data showed it was well tolerated at all doses administered, with no unexpected adverse events |
6/12/12 |
GlaxoSmithKline plc (London) |
Albiglutide |
Glucagon-like peptide 1 receptor agonist |
Type II diabetes |
Phase III data showed a beneficial effect on HbA1c, however statistical significance was lost, and it failed to show noninferiority to liraglutide |
6/12/12 |
Halozyme Therapeutics Inc. (San Diego) |
Lispro or aspart |
Two rapid-acting insulin analogue products, formulated with recombinant human hyaluronidase enzyme |
Type II diabetes |
Phase II trial met its primary endpoint showing that the formulations were noninferior for A1C, compared to lispro alone with no treatment difference |
6/12/12 |
Janssen Research & Development LLC (Raritan, N.J.) |
Canagliflozin |
A sodium glucose co-transporter 2 |
Type II diabetes |
Data from five Phase III trials were presented, showing it provided substantial and sustained glycemic improvements in adults and was generally well tolerated |
6/11/12 |
Metabolic Solutions Development Co. LLC (Kalamazoo, Mich.) |
MSDC-0160 |
A once-daily oral insulin sensitizer |
Type II diabetes |
Phase IIb data showed it met the primary endpoint of significantly reducing fasting plasma glucose |
6/12/12 |
Novo Nordisk A/S (Bagsvaerd, Denmark) |
Degludec |
Ultra-long-lasting insulin degludec |
Type II diabetes |
Significantly reduced the rate of hypoglycemia at night in adults with Type II diabetes |
6/25/12 |
Sanofi SA (Paris) |
Lixisenatide |
Once-daily oral glucagon-like peptide-1 |
Diabetes |
Sanofi filed for approval in Japan |
6/12/12 |
Sanofi SA (Paris) |
Lantus |
Insulin glargine |
Type II diabetes |
Data showed diabetics who were uncontrolled on metformin demonstrated superior HbA1c-glycated hemoglobin reduction with Lantus vs. Januvia; data showed no statistically significant positive or negative impact on cardiovascular outcomes compared to standard of care duing the six-year study period and no association with increased risk of any cancer |
6/12/12 |
Zafgen Inc. (Cambridge, Mass.) |
Beloranib |
A selective methionine aminopeptidase 2 inhibitor |
Obesity |
Phase I data showed it led to significant weight loss and improvements in cardiometabolic risk markers |
6/11/12 |
|
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. | |||||